| Recruiting | Safety, Tolerability, and Immunogenicity of VAX-31 in Adults ≥50 Years With Prior Pneumococcal Vaccination NCT07425392 | Vaxcyte, Inc. | Phase 3 |
| Active Not Recruiting | A Clinical Study to Evaluate the Safety, Tolerability, and Immunogenicity of VAX-31 With Influenza Vaccine in NCT07365826 | Vaxcyte, Inc. | Phase 3 |
| Not Yet Recruiting | Opportunistic Pneumococcal Immunisation Trial in MALnutrition NCT06817421 | Nick Fancourt | Phase 4 |
| Not Yet Recruiting | Evaluation of PCV21 Vaccination Among PPSV23-experienced, Immunocompromised Elderly Veterans NCT06271681 | VA Sierra Nevada Health Care System | Phase 4 |
| Active Not Recruiting | Safety, Tolerability, and Immunogenicity of VAX-31 in Adults ≥50 Years With Immunobridging to Adults 18-49 NCT07284654 | Vaxcyte, Inc. | Phase 3 |
| Completed | Phase I/II Clinical Trial of 26-valent Pneumococcal Conjugate Vaccine NCT06703203 | Beijing Zhifei Lvzhu Biopharmaceutical Co., Ltd | Phase 1 / Phase 2 |
| Active Not Recruiting | A Clinical Study to Evaluate the Safety, Tolerability, and Immunogenicity of VAX-31 in Healthy Infants NCT06720038 | Vaxcyte, Inc. | Phase 2 |
| Recruiting | A Phase 3 Study to Evaluate the Immunogenicity and Safety of Minhai's PCV13-DT/TT Vaccine As Compared to Pfize NCT06608199 | Beijing Minhai Biotechnology Co., Ltd | Phase 3 |
| Completed | Safety, Tolerability, and Immunogenicity Study of a 31-Valent Pneumococcal Conjugate Vaccine (VAX-31) in Adult NCT06151288 | Vaxcyte, Inc. | Phase 1 / Phase 2 |
| Recruiting | Reminder Emails to Improve Pneumococcal Vaccine Completion at 12 Months of Age NCT06000397 | Ottawa Hospital Research Institute | N/A |
| Completed | Dose-Ranging Study to Evaluate a 25-Valent Pneumococcal Conjugate Vaccine NCT06077656 | Inventprise Inc. | Phase 2 |
| Unknown | Evaluation of the Non-Inferiority of a 12-Valent Pneumococcal Conjugate Vaccine in Healthy Children in Brazil. NCT05721456 | Maria de Lourdes de Sousa Maia, MD | Phase 3 |
| Completed | Safety, Tolerability, and Immunogenicity of a 24-Valent Pneumococcal Conjugate Vaccine (VAX-24) in Healthy Inf NCT05844423 | Vaxcyte, Inc. | Phase 2 |
| Completed | Study to Evaluate a 25-Valent Pneumococcal Conjugate Vaccine NCT05540028 | Inventprise Inc. | Phase 1 |
| Completed | Safety, Tolerability, and Immunogenicity Study of a 24-Valent Pneumococcal Conjugate Vaccine (VAX-24) in Older NCT05297578 | Vaxcyte, Inc. | Phase 2 |
| Completed | Safety, Tolerability, and Immunogenicity Study of a 24-Valent Pneumococcal Conjugate Vaccine (VAX-24) in Adult NCT05266456 | Vaxcyte, Inc. | Phase 1 / Phase 2 |
| Unknown | Combined Immunization of COVID-19 Inactivated Vaccine With QIV and PPV23 NCT05298800 | Centers for Disease Control and Prevention, China | Phase 4 |
| Completed | Safety, Tolerability, and Immunogenicity of V114 in Healthy Infants (V114-029) NCT03893448 | Merck Sharp & Dohme LLC | Phase 3 |
| Unknown | Mechanisms of Impaired HIV-associated B Cell and Pneumococcal Vaccine Responses NCT02012309 | University of Colorado, Denver | N/A |
| Completed | 13vPnC Multidose Vial Safety, Tolerability and Immunogenicity Study in Healthy Infants. NCT01964716 | Pfizer | Phase 3 |
| Completed | Trial of Pneumococcal Vaccine Schedules in Ho Chi Minh City, Vietnam NCT01953510 | Murdoch Childrens Research Institute | Phase 2 / Phase 3 |
| Completed | A Phase 3 Trial Evaluating the Safety, Tolerability, and Immunogenicity of a 13-valent Pneumococcal Conjugate NCT01646398 | Pfizer | Phase 3 |
| Completed | Phase I Safety Trial of Streptococcus Pneumoniae Whole Cell Vaccine (SPWCV) + Alum in Healthy Adults NCT01537185 | PATH Vaccine Solutions | Phase 1 |
| Completed | Study Assessing the Effect of Medications to Prevent Fever on Prevenar 13® NCT01392378 | Pfizer | Phase 4 |
| Completed | Study Evaluating 13-valent Pneumococcal Conjugate Vaccine in Healthy Children NCT00824655 | Pfizer | Phase 3 |
| Unknown | Conjugate And Polysaccharide Vaccines Compared With Polysaccharide Vaccine In Hiv-Infected Adults NCT00999739 | Hospital Universitari Son Dureta | Phase 3 |
| Completed | Study Evaluating the Safety, Tolerability and Immunogenicity of 13vPnC as a 2-Dose Regimen or With 23vPS NCT00574548 | Wyeth is now a wholly owned subsidiary of Pfizer | Phase 3 |
| Completed | Wyeth Study To Evaluate a 13-valent Pneumococcal Conjugate Vaccine in Infants NCT00464945 | Wyeth is now a wholly owned subsidiary of Pfizer | Phase 3 |